What the FDA decided
One of the FDA’s jobs, stated on that COVID update, is to evaluate whether a drug is both safe and effective for a particular use. Interest in ivermectin for prevention or treatment of COVID-19 in humans has not changed the answer for this use: no authorization, no approval, in people or in animals.
For humans, ivermectin tablets are approved at specific doses to treat some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. On the U.S. Stromectol label those oral infections are named plainly: STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis, and for onchocerciasis due to Onchocerca volvulus. For animals, pour-on, injectable, paste, chewable, and “drench” products treat or prevent parasites in livestock and pets. Those animal products are formulated differently and are safe only when used in animals as labeled or prescribed.
The FDA has received multiple reports of patients who have required medical attention, including hospitalization, after self-medicating with ivermectin intended for animals. Taking large doses of ivermectin can be dangerous. Overdose can cause nausea, vomiting, diarrhea, hypotension (low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (problems with balance), seizures, coma and even death. Even labeled human doses can interact with other medicines, including blood thinners. A prescription for a real parasite is filled as a human product—not scooped from a feed-store tube.
The page also points readers toward current CDC guidance on lowering risk from common respiratory viral illnesses, including COVID-19, and toward talking with a clinician about available vaccines and treatment options that match a person’s history. This article does not invent a COVID milligram table.
What large outpatient trials actually measured
Early laboratory work suggested ivermectin might slow SARS-CoV-2 in cells. A hit in a dish is a reason to run a careful human trial. It is not, by itself, a treatment.
ACTIV-6 tested that question in U.S. outpatients with mild to moderate COVID-19. In the JAMA report (October 2022), adults 30 and older with confirmed infection and recent symptoms were enrolled across 93 sites. Participants were randomized to receive ivermectin, 400 μg/kg (n = 817), daily for 3 days or placebo (n = 774). The primary endpoint was time to sustained recovery—at least three consecutive days without symptoms—with hospitalization or death by day 28 among the secondary outcomes. Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. Median recovery times were 12 days (ivermectin) and 13 days (placebo); hospitalization or death by day 28 was uncommon in both arms (about 1.2% each in the abstract’s count).
A separate early-treatment trial (Reis and colleagues) enrolled symptomatic adults from public clinics in Brazil who had had COVID-19 symptoms for up to seven days and at least one risk factor for progression. Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. That is a different geography and a different primary composite—but the same practical reading: early outpatient ivermectin did not clear the bar the trial set for preventing serious care escalation.
Smaller early studies and later retracted papers still circulate in screenshots. A 72-person hospital sample with a lab clearance endpoint is not the outpatient record ACTIV-6 and Reis tested. This page does not rebuild a gallery of every retracted preprint. It stays with the authorization line and the large early-treatment results above.
Veterinary products are not a human COVID protocol
Animal ivermectin is approved to prevent heartworm and treat certain parasites in animals. Concentrations, inactive ingredients, and dosing assume a cow, horse, or dog—not a person measuring paste against a rumor. The FDA’s hospitalization reports after animal-product self-medication are the operational reason this section exists: the tube is not a workaround for the missing COVID authorization.
If someone has already swallowed a veterinary product, poison-control help and the container matter more than waiting to see whether dizziness passes. Human milligram tables for labeled parasite courses are on the dosing guide—not a COVID schedule invented here.
What stays approved
Nothing in the COVID record removes intestinal strongyloidiasis or onchocerciasis from the U.S. oral Stromectol label. Those indications—and the empty-stomach, weight-based rates that go with them—are still the jobs the tablet names. COVID-19 does not appear among them. For which parasites the oral tablet names, and how the molecule opens invertebrate chloride channels, use the uses page. For tablet-count bands, use the dosing guide.
A cheap bottle and a Nobel Prize for river blindness do not rewrite the FDA’s COVID decision. Talk with a clinician about vaccines and treatments that are actually authorized or recommended for COVID-19 in your situation—and keep ivermectin for the parasites it is labeled to treat when that is the diagnosis on the script.
Next step
If you are asking about a named parasite, open the uses page and then the weight table. If you are asking about COVID-19, you take the FDA decision on this page to a clinician. You do not substitute a livestock tube.